Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

Completed · Phase 2

Conditions studied: Melanoma

In brief

To assess the response of melanoma with brain metastases to ipilimumab treatment while maintaining acceptable tolerability.

Key facts

Study ID

NCT00623766

Run by

Bristol-Myers Squibb

People needed

99

Starts

2008-07-01

Expected to finish

2012-10-01

Last updated by the study team

2014-06-09

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Mayo Clinic Arizona — Scottsdale, Arizona, United States
• City Of Hope — Duarte, California, United States
• The Angeles Clinic & Research Institute — Los Angeles, California, United States
• Yale University School Of Medicine — New Haven, Connecticut, United States
• Loyola University Medical Center — Maywood, Illinois, United States
• Oncology Specialists, S.C. — Park Ridge, Illinois, United States
• Indiana University Cancer Center — Indianapolis, Indiana, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Local Institution — The Bronx, New York, United States
• Providence Portland Med Ctr — Portland, Oregon, United States
• Vanderbilt-Ingram Cancer Ctr — Nashville, Tennessee, United States
• Seattle Cancer Care Alliance — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.